Potassium voltage-gated channel interacting protein 3 (KCNIP3)

Potassium voltage-gated channel interacting protein 3 (KCNIP3) is a small, multifunctional, calcium-binding protein within the EF-hand superfamily that acts as a modulatory subunit of A-type (Kv4) voltage-gated potassium channels, regulating their inactivation and membrane expression in a calcium-dependent manner[1][3]. KCNIP3 is also known as calsenilin, DREAM, and KChIP3, among other aliases, and serves an additional function as a calcium-regulated transcriptional repressor that binds directly to DRE (downstream regulatory element) motifs of target genes, with affinity modulated by calcium and magnesium[1][3]. The protein interacts with presenilins, impacting amyloid-beta production and apoptosis, and has been linked to neurodegenerative diseases such as Alzheimer’s disease, as well as epilepsy and other neurological conditions. While crucial for neuronal excitability regulation, there are currently no approved drugs that directly target KCNIP3, and its role in disease makes it of research interest rather than a current clinical biomarker or therapeutic target[1][3][5].

Other names

CalsenilinDREAMKChIP3CSENA-type potassium channel modulatory protein 3DRE-antagonist modulatorKv channel-interacting protein 3presenilin-binding proteinEF-hand transcription factor

Not applicable for approved drugs; for experimental modulation, mechanisms would involve **modulation of Kv4 channel inactivation properties** and/or **block of KCNIP3 transcriptional repressor activity**, influencing calcium and potassium signaling and downstream gene expression